DAX+1,41 % EUR/USD-0,28 % Gold+0,57 % Öl (Brent)-2,05 %

CombiMatrix nach reverse-split 1 für 10* - 500 Beiträge pro Seite

Beitrag schreiben

Begriffe und/oder Benutzer


Hi CombiMatrix startet nach reverse-split 1ne Neue Aktie für 10 alte Aktien durch*

After reverse-split 1:10* kam es bei CBMX zu einem Kurs-Anstieg um über 333%*

siehe cbnc.com


8.60 USD
Close Price 6.63 (+336.55%)
Volume 4:00:00 PM EST
Market Close

Wünsche Alle ein erholsames WE*

LG where-
Nach einem solchen Mega-Anstieg müßte eigentlich eine Konso-Phase folgen?

Außerdem lag der short-Anteil vom 19 November- 28 November bis auf einen einzigen Handelstag(absolut geringes Handelsvolumen) immer über 52% bis einmalig über 91% short-Anteil,

Date VolShorted High Low Close Chg
Dec 07 42.18% 9.49 1.97 8.60 +336.55%

Wie schon erwähnt dürfte es mit über 90 Prozentiger Sicherheit zu einem weiteren(außerdem nachbörslichen vom Freitag) Kursrückgang kommen,
welcher sehr häufig bei Splits,
auch ohne einen wie zuletzt stattgefundenen Kursanstieg, fast immer gängige Praxis ist*!

Nur meine Meinung keine Kauf- oder Verkaufsempfehlung ...*!

LG where-
shorter Waaaaaaaaaahnsin an der Nasdaq bei CBMX*

11.25 USD
Last Trade 2.65 (+30.81%)
Volume 10:21:35 AM EST
Trade Time
theoretisch schon nach ca. 70 Minuten das komplette Aktienpaket durchgehandelt?

11.58 USD
Last Trade 2.98 (+34.65%)
Volume 10:39:53 AM EST
Trade Time

Das macht doch mehr als deutlich, das die meisten Kursfestellungen nichts mit irgentwelchen Daten oder Fakten zu tun hat,
sonder das meisten Kurse nur durch die Angst und die Gier der Anleger die Kurse generiert werden,

NmM-Keine Handelsempfehlung*

LG where-

P.s. Wer ich immer noch kauft und später Verluste einfährt ist 100 Prozentig selbst SCHULD*

Vor wenigen Tagen gerade mal 1 zehntel des Kurswertes*** der absolute Wahnsinn***
Neue Kennung für CBMX-CombiMatrix nach resplit:

ISIN: US20009T3032 | WKN: A1J9L5 | Symbol: AZG4
Biotech Weekly Recap: The Market Holds While Biotech Crumbles
December 9, 2012
The biggest counter-example to my statement that biotech was bearish this week was the move in CombiMatrix (NASDAQ: CBMX) on Friday. Shares jumped 366% on the findings published in the New England Journal of Medicine, which showed that chromosomal microarray analysis was simply better than standard karyotyping for genetic analysis. This is a big deal to the scientific community, and a huge deal to CombiMatrix, who specializes in chromosomal microarray analysis.

There are many diagnostic tests that use genetic testing, and Wall Street expects CombiMatrix to have a much better future now that chromosomal microarray analysis got a giant popularity boost in the world of diagnostics. Expect Combimatrix to get a lot more volatile as the market attempts to gauge just how much better CombiMatrix's prospects have gotten.
CombiMatrix Skyrockets After Important Medical Publication
December 11, 201

The diagnostics company CombiMatrix Corporation (NASDAQ: CBMX) saw weak trading for the entirety of 2012 until last Friday (December 7, 2012) when company stock jumped 336.6% in reaction to a publication in the New England Journal of Medicine. While YTD (year to date) gains in the stock still sit at -57%, the recent move was a clear sign that investor perception on CBMX may finally be changing for the better.

CombiMatrix's history as a public company goes all the way back to its IPO at the end of 2002, when the company was initially listed on the NASDAQ at $326/share. While CombiMatrix has now developed an array of diagnostic tests for oncology as well as developmental disorders, the company has also been continuously diluting shares and has not made all that much progress in terms of growth in sales revenue considering how long it has been in operation. In the third quarter of 2012, the company reported total revenues of only $1.3 million. While a positive trend in revenue growth is a good sign for future quarters, $1.3 million is simply not enough for CombiMatrix to cover its operating expenses of over $2.6 million each quarter.

Judging by the action we saw last Friday, it seems that the market is considering the possibility that the recently published research mentioned earlier could provide a much-needed lift to CombiMatrix's sales volumes.

The NIH (National Institutes of Health) performed the largest head-to-head study comparing something known as chromosomal microarray analysis (CMA) to karyotyping for the analysis of genetic diseases in the prenatal diagnostic setting, as well as stillbirths. What got investors really excited were statements made by the renowned reproductive geneticist Dr. Ronald Wapner, calling for a replacement of the traditional karyotype-based genetic analysis with chromosomal microarray analysis. According to his statements, karyotypes provide less information than chromosomal microarrays and hence reduce the accuracy of genetics testing for diseases. Karyotyping has essentially become outdated, replaced by the vastly superior chromosomal microarray analysis.

Helping this statement were results from the study entitled "Chromosomal Microarray Versus Karyotyping for Prenatal Diagnosis," which enrolled a total of 4,406 women. Microarray analysis gave successful diagnostic results in 98.8 percent of women, and caught mistakes that were made with traditional karyotyping diagnostics. 755 women out of the population that had normal karyotypes were tested due to suspected growth or structural anomalies - 45 were found to have clinically relevant findings. Out of the total number of women that had normal karyotypes that implied standard indications for prenatal diagnosis, 1.7% of pregnancies were found to have clinically relevant information due to chromosomal microarray analysis.

It's also worth noting that a second study was mentioned in the publication, which showed that CMA is capable of performing genetic analysis on dead tissue. This allows for accurate genetic profiling of stillbirths, which is a big development for geneticists.

While CombiMatrix moved up over three times its previous market capitalization on this news alone, it's worth noting that the company is still quite small in terms of market capitalization, at $9.2 million. While the cash burn rate of the company (about $5.3 million per year) is eating away at shareholder value very quickly, the market was willing to drastically boost the value of CombiMatrix due to the notion that its sales revenue could jump quite significantly in 2013.

Many doctors are unaware that chromosomal microarray genetic analysis is vastly superior to karyotyping, but the publication in the New England Journal of Medicine will certainly draw a lot of attention to this realization. Since CombiMatrix is focused on diagnostic products that are based on CMA, we should expect sales volume to improve drastically next year as more labs switch from karyotyping to CMA tests. Another trend that could improve CombiMatrix's financial situation is its cost-cutting efforts. In Q3, the company's total expenses were 53% higher than they were this year. CombiMatrix has a good chance of becoming profitable as early as next year given that labs begin the switch from karyotype-based analysis to CMA analysis fast enough.

Investors who are interested in CombiMatrix should really be keeping their eyes on the sales growth of the company's diagnostic product line for genetic diseases next year, as well as the company's expenses to gauge the company's trajectory.
CombiMatrix Reports Preliminary Annual Growth in Prenatal Testing Volumes of 172% and 171% for Fourth Quarter and Year, Respectively
Company Refocused Commercial Resources on Prenatal and Pediatric Markets Mid-2012

IRVINE, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it expects to report record volumes of prenatal testing in the fourth quarter and year ended December 31, 2012. Preliminary annual growth rates of 172 percent and 171 percent were achieved for billable prenatal tests in the quarter and full year, respectively. The rapid growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis (CMA) is becoming the standard of care. CombiMatrix is the only publicly-traded company that specializes in CMA.

R. Judd Jessup, President and CEO of CombiMatrix said, "Our refocused commercial strategy began to kick in during the latter half of 2012 and especially in the fourth quarter. We believe our focus on CMA in the prenatal and pediatric segments is allowing us to gain traction and marketshare as the technology landscape and standard of care changes. In addition, recent key clinical publications bolstering that paradigm shift should continue to add momentum in those markets as 2013 progresses."

Late in 2012, a pair of studies published in the New England Journal of Medicine, favored CMA over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. The two large studies, published in the December edition of the Journal, represented the largest head-to-head studies comparing CMA to traditional karyotyping. Both concluded that CMA identified additional, clinically significant genetic abnormalities compared to karyotyping in both the prenatal diagnostic setting as well as the evaluation of stillbirths.

Jessup continued, "CMA gives parents, physicians and educators better tools for anticipatory care by proactively addressing the impacts of many chromosomal disorders. In the case of stillbirths or miscarriages, CMA can be used to determine if there is a genetic reason for these occurrences, especially when it happens more than once, and can give parents valuable information about future pregnancies."

Overall billable testing volumes at the Company, including its de-emphasized oncology segment, was also up strongly in the period, growing 21 percent and 25 percent in the quarter and full year, respectively, over 2011. CombiMatrix expects to report its operating results in late February, 2013 and file its annual report for 2012 on Form 10-K in mid-March, 2013. The Company will issue a press release and hold an investor conference call to discuss results.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
Das Ding geht durch die Decke und hier schreibt keine Sau was dazu. Ich Idiot habe meine Teile in Panik vor einer Woche verkauft.

Der Buffet hat einfach nur recht. Das Hin- und Hergeschiebe bringt nur Verluste ein.

Den Geduldigen und Mutigen gehört die Welt.
Hi Aurakel und andere User:

Versucht's doch mit der neuen WKN von COMBI-MATRIX,
vllt. einen neuen thread eröffnen, dann kannste auch den Thread-Master stellen*!


*** Hin und her macht Taschen leer? ***
Stimmt nicht immer aber ziemlich oft*
Als Langfrist Anleger gibt es vllt bessere Posis?*

Denn Bio-Werte sind doch immer mit viel Risiko verbunden*!

P.s. Ich Euch Allen viel Glück bei Eueren trades*!

LG where-
Antwort auf Beitrag Nr.: 44.174.691 von where-is-the-insider am 22.02.13 15:28:26

Danke für Deine Infos!
Ich bin Deiner Anregung gefolgt:

Neue Diskussion unter dem Eindruck des Q4-Berichts:

CombiMatrix - Strategische Neuausrichtung auf Prenatal-Tests mit CMA (chromosomal microarray analysis)
Hier bitte keine Beiträge mehr einstellen,
weil für CombiMatrix eine neue Wertpapierkennnummer+ ein neuer Forums-thread exisitiert*!

Bitte für INFOs oder Beiträge diesen link nützen ....


LG where-

Beitrag zu dieser Diskussion schreiben

Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.